NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines.
With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.
Net income (FY, 2016)
EBITDA (FY, 2016)
EBIT (FY, 2016)